ZYNTRUVO Trademark

Trademark Overview


On Wednesday, April 5, 2023, a trademark application was filed for ZYNTRUVO with the United States Patent and Trademark Office. The USPTO has given the ZYNTRUVO trademark a serial number of 97874087. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, October 30, 2024. This trademark is owned by Teva Pharmaceuticals International GmbH. The ZYNTRUVO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations
zyntruvo

General Information


Serial Number97874087
Word MarkZYNTRUVO
Filing DateWednesday, April 5, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, October 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 19, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood and circulatory diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, endocrine diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, metabolic diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, urogenital diseases and disorders, and urinary diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, infectious diseases, inflammatory conditions, menopause, ophthalmic disorders and diseases, pain, and psychological disorders; pharmaceutical preparations for use in smoking cessation; contraceptive preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, April 8, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals International GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressJona 8645
CH

Party NameTeva Pharmaceuticals International GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressJona 8645
CH

Trademark Events


Event DateEvent Description
Saturday, April 8, 2023NEW APPLICATION ENTERED
Saturday, April 29, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, January 1, 2024ASSIGNED TO EXAMINER
Monday, January 1, 2024NON-FINAL ACTION WRITTEN
Monday, January 1, 2024NON-FINAL ACTION E-MAILED
Monday, January 1, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 1, 2024FINAL REFUSAL WRITTEN
Thursday, February 1, 2024FINAL REFUSAL E-MAILED
Thursday, February 1, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 14, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, February 14, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, February 14, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, February 14, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, February 14, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 28, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 28, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2024PUBLISHED FOR OPPOSITION
Tuesday, March 19, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, October 30, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 30, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 30, 2024SOU EXTENSION 1 FILED
Wednesday, October 30, 2024SOU EXTENSION 1 GRANTED
Tuesday, May 14, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT